Min Hwan Kim
Overview
Explore the profile of Min Hwan Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim H, Baek S, Han S, Kim G, Sohn J, Rhee Y, et al.
J Cachexia Sarcopenia Muscle
. 2024 Dec;
16(1):e13666.
PMID: 39686815
Background: Recent evidence indicates that a dysregulated host metabolism influences treatment outcomes in patients with breast cancer. We investigated the association of computed tomography (CT)-derived body composition indices with therapeutic...
2.
Park C, Suh K, Kim S, Lee K, Im S, Kim M, et al.
Cancer Immunol Immunother
. 2024 Aug;
73(10):197.
PMID: 39105849
Background: Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment...
3.
Iwata H, Xu B, Kim S, Chung W, Park Y, Kim M, et al.
Cancer Sci
. 2024 Jul;
115(9):3079-3088.
PMID: 38979893
The global phase 3 DESTINY-Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T-DXd) over trastuzumab emtansine...
4.
Ahn J, Kim M, Lee K, Oh K, Lim H, Kil H, et al.
EJNMMI Res
. 2024 Jul;
14(1):59.
PMID: 38958796
Background: N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT), the representative cocaine derivative used in dopamine transporter imaging, is a promising biomarker, as it reflects the severity of Parkinson's disease (PD). I- and F-labeled FP-CIT...
5.
Park S, Ryu W, Kim T, Hwang Y, Han H, Lee J, et al.
Exp Mol Med
. 2024 Apr;
56(4):987-1000.
PMID: 38622197
Transcriptional programs governed by YAP play key roles in conferring resistance to various molecular-targeted anticancer agents. Strategies aimed at inhibiting YAP activity have garnered substantial interest as a means to...
6.
Choi J, Jin L, Jeon M, Kim M, Yang S, Sohn M
Dev Med Child Neurol
. 2024 Feb;
66(8):1096-1105.
PMID: 38303153
Aim: We compared three different intensities of robot-assisted gait training (RAGT) for achieving favourable outcomes in children with cerebral palsy (CP). Method: This study was conducted using a randomized controlled,...
7.
Baek S, Jeong J, Jung K, Ahn H, Kim M, Sohn J, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231225029.
PMID: 38288157
Purpose: This study aimed to investigate clinical practices and factors related to the outcomes of T-DM1 use in patients with HER2-positive metastatic breast cancer (mBC). Methods: We included patients with...
8.
Kim K, Lee Y, Kim M, Byun B, Woo S
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255324
The purpose of this study was to investigate the most appropriate methodological approach for the automatic measurement of rodent myocardial infarct polar map using histogram-based thresholding and unsupervised deep learning...
9.
Kim M, Lee J, Yang S
Brain Neurorehabil
. 2023 Dec;
16(3):e35.
PMID: 38047097
Fibromuscular dysplasia (FMD) is a congenital vascular anomaly resulting in arterial stenosis and weakening of typically medium-sized arteries. It is a noninflammatory, nonatherosclerotic arterial disease that affects most commonly the...
10.
Takahashi M, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al.
JAMA Netw Open
. 2023 Nov;
6(11):e2342107.
PMID: 37966841
Importance: In the phase 3 KEYNOTE-522 study, addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab significantly increased pathologic complete response (pCR) and event-free survival (EFS) vs neoadjuvant chemotherapy...